Closing market on Friday at the $1.24 mark, EVFM stock gathers the attention of investors and willing to soar by 3% today. What caused such a boost, and should we expect to see a progressive mark in June and July? Throughout the past week, the company’s stock is surging from $1.005 to $1.24 for today. However, in comparison with May, it is just recovering, reaching a mark of $1.24.
In September 2020, Evofem Biosciences (EVFM), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, released Phexxi®, its first FDA-approved commercial product, leading the stock to its highest peak ($4.62). Thus, the company has great chances to blow up the market, realizing new products, which are currently at the testing stage, in phase 3 out of 5.
The release of goods is expected in the coming months, which could affect the stock; nevertheless, the stock is predicted to gain in the coming years, and the short-term price is dependent on the company’s releases and news.
Finance and Tech Contributor